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Edited by Ulf-Ingo Flu¨ggeAbstract With regard to structure–function relations of ATP-
binding cassette (ABC) transporters several intriguing questions
are in the spotlight of active research: Why do functional ABC
transporters possess two ATP binding and hydrolysis domains
together with two ABC signatures and to what extent are the
individual nucleotide-binding domains independent or interact-
ing? Where is the substrate-binding site and how is ATP hydro-
lysis functionally coupled to the transport process itself?
Although much progress has been made in the elucidation of
the three-dimensional structures of ABC transporters in the last
years by several crystallographic studies including novel models
for the nucleotide hydrolysis and translocation catalysis, site-di-
rected mutagenesis as well as the identiﬁcation of natural muta-
tions is still a major tool to evaluate eﬀects of individual amino
acids on the overall function of ABC transporters. Apart from
alterations in characteristic sequence such as Walker A, Walker
B and the ABC signature other parts of ABC proteins were sub-
ject to detailed mutagenesis studies including the substrate-bind-
ing site or the regulatory domain of CFTR. In this review, we
will give a detailed overview of the mutation analysis reported
for selected ABC transporters of the ABCB and ABCC subfam-
ilies, namely HsCFTR/ABCC7, HsSUR/ABCC8,9, HsMRP1/
ABCC1, HsMRP2/ABCC2, ScYCF1 and P-glycoprotein
(Pgp)/MDR1/ABCB1 and their eﬀects on the function of each
protein.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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ATP-binding cassette (ABC) proteins are present in all
organisms from bacteria to humans, mediating the transloca-
tion of substances into and out of cells or organelles [1]. In hu-
mans, genetic defects of these proteins have been implicated in
several diseases involving transport deﬁciencies. For these rea-
sons, understanding the structure and function of this class of
proteins is an important aim. For several ABC transporters
including the human multidrug resistance associated proteins
(HsMRP1/ABCC1 and HsMRP2/ABCC2), the yeast cadmium
factor 1 (ScYCF1), the cystic ﬁbrosis transmembrane conduc-
tance regulator (CFTR/ABCC7) and the sulfonylurea receptor
(SUR/ABCC8 and 9), site-directed mutagenesis of amino acid*Corresponding author. Fax: +41 1 634 8204.
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as well as analysis of mutations occurring in patients or animal
models suﬀering from diseases associated with changes in
MRP-like genes (e.g., cystic ﬁbrosis) have led to the elucida-
tion of the role of single amino acids in the overall function
of the protein with an emphasis on alterations aﬀecting ATP
hydrolysis and/or binding and transport of compounds
through the membrane.
Full size ABC transporters have two NBDs with character-
istic sequences: two Walker A and B domains [2] which bind
ATP required for substrate transport and the ABC signature
[3]. The Walker A and B consensus sequences are both known
to be intimately involved in and required for the ATP hydro-
lysis reaction [4–9]. Inactivation of the ATP hydrolysis reac-
tions by mutations in these sequences leads to commensurate
loss of ATP-driven drug eﬄux from cells. A third conserved se-
quence ‘‘LSGGQ’’ which is named the ABC signature se-
quence because it is the hallmark of the ABC transporter
superfamily is found between the Walker A and B sequences
[1,10]. The strong conservation of this sequence in evolution
implies an important role. Yet, its functional signiﬁcance is still
a matter of investigations. Figs. 1 and 2 illustrate proposed
two-dimensional structures of ABC transporter discussed in
this review and a multiple alignment of the amino acid se-
quences of the two NBDs of HsMRP1, HsMRP2, HsCFTR,
HsSUR1 and ScYCF1 highlighting the Walker domains and
the ABC signature, respectively.
For the above mentioned ABC transporters, function, local-
ization and disease linked to mutations have already been re-
ported. In man, HsMRP1 has a very broad substrate
spectrum relative to many other ABC transporters. Consis-
tently, drug-selected tumor cell lines overexpressing this pro-
tein exhibit increased resistance to natural product drugs
such as anthracyclines, Vinca alkaloids and epipodophyllotox-
ins, as well as folic acid analogs (methotrexate), arsenic and
antimony-centered oxyanions. HsMRP1 is a primary active
transporter of a wide variety of conjugated and unconjugated
organic anions, many of which are conjugated to anionic moi-
eties glutathione (GSH), glucuronide and sulfate [11,12].
HsMRP1 is expressed in most tissues in the human body with
relatively higher levels found in the lung, testis, kidney, muscle
and peripheral blood mononuclear cells [13,14]. In polarized
epithelial cells, HsMRP1 is usually localized to basolateral
membranes. Another HsMRP, HsMRP2, shares 49% amino
acid identity with HsMRP1 while the range of endo- and xeno-
biotic molecules transported by both is comparable. Mutations
in MRP2 cause a mild conjugated hyperbilirubinemia known
as Dubin–Johnson syndrome [15]. However, substantial diﬀer-blished by Elsevier B.V. All rights reserved.
Fig. 1. Two-dimensional structures of CFTR/ABCC7 (A), ‘long’
MRP-type transporters HsMRP1/ABCC1, HsMRP2/ABCC2, human
SUR isoforms SUR1/ABCC8, SUR2/ABCC9 and yeast YCF1 (B) and
Pgp/MDR1/ABCB1 (C). The TMDs and NBDs are indicated. Black
boxes designate the conserved Walker A (A), Walker B (B) and the
ABC signature (ABC). In CFTR, the position of the regulatory
domain (R) is indicated. CFTR and Pgp are composed of two TMDs
and two NBDs with 12 TM helices. The ‘long’ MRPs additionally
possess an N-terminal hydrophobic extension designated as TMD0
resulting in 17 TM helices.
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ated transport of organic anions is stimulated by many com-
pounds, some of which inhibit the transport activity of
HsMRP1 [16]. HsMRP2 is mainly abundant in hepatocytes,
predominantly in canalicular membranes where it plays an
important role in the biliary excretion of endogenous and
exogenous anionic conjugates such as bilirubin glucuronides
[11,14,15]. In polarized cells, HsMRP2 is found in the apical
membranes.
Interestingly, two other human ABC transporters, CFTR
and SUR, have been reported to interact with or regulate other
channels. The most common fatal autosomal recessive genetic
disease aﬀecting Caucasian populations, cystic ﬁbrosis, is
caused by mutations of CFTR [17]. Approximately 80% of
all mutations are located within the NBDs (http://
www.genet.sickkids.on.c./cgibin/WebObjects/MUTATION).
This protein has been demonstrated to be a phosphorylation-
dependent membrane chloride channel [18] that acts in the api-
cal membrane of epithelial cells to promote ﬂuid transport
across tubular or ductural organs. The lack of CFTR channel
function increases viscosity of the luminal contents of these or-
gans. Most naturally occurring mutations in the CFTR gene
are either inducing an alteration in protein biosynthesis or
leading to defective channel function. CFTR is a regulated
ion channel [19–21].
SUR forms the regulatory subunit of the ATP-sensitive
potassium (KATP) channels, together with the pore-formingand inwardly rectifying K+ channel Kir6.0 [22]. Diﬀerent sub-
types exist: SUR1/ABCC8, SUR2A and SUR2B (SUR2 is also
termed ABCC9), characteristic for pancreatic, cardiac and vas-
cular smooth muscle-type KATP channels, respectively [23–26].
These channels are associated with cellular functions such as
insulin secretion, cardiac preconditioning, vasodilatation and
neurotransmitter release by linking the cellular metabolic state
to the membrane potential [27]. Diﬀerent authors have re-
viewed structure–function relationships and regulation of
KATP channels [28–31].
Pgp, also known as multidrug-resistance protein MDR1/
ABCB1, is a plasma-membrane located glycoprotein which
confers multidrug-resistance phenotype on cells by virtue of
its ability to exclude cytotoxic drugs in an ATP-dependent
manner. Pgp acts as an ATP-driven drug-export pump by cou-
pling ATP binding and hydrolysis at two cytoplasmic NBDs to
drug export via two transmembrane domains (TMDs). The
mechanism involves presentation of transport substrates to
the pump from the lipid membrane phase. An extraordinarily
wide range of compounds act as substrates. Multidrug resis-
tance is an important obstacle in treatment of human cancer,
and there is considerable interest in the potential role of Pgp
in rendering tumor cells resistant to chemotherapeutic drugs
[32–36].
In Saccharomyces cerevisiae, ScYCF1 represents a vacuolar
membrane protein involved in heavy metal and drug detoxiﬁ-
cation. Disruption of the gene results in a yeast strain hyper-
sensitive to cadmium [37]. ScYCF1 is an ATP-dependent
pump able to transport organic glutathione-S-conjugates
(GS-conjugates) into the vacuole [38], GS–metal complexes,
glutathione and other compounds like bilirubin [39]. This pro-
tein can transport the physiological substrate of HsMRP1, leu-
kotriene C4 (LTC4) representing a GS-conjugate [39,40].
ScYCF1 may thus be an excellent model for examining struc-
ture–function issues relating to human MRP1 and eukaryotic
ABC transporters in general. As all members of the ABC
superfamily, YCF1 is formed by two TMDs and two NBDs
[37], a putative regulatory domain and a third N-terminal
TMD present only in the MRP-subfamily [41]. Yeast is an
excellent experimental system and the cadmium-hypersensitiv-
ity of Dycf1 yeasts as well as high capacity of GS-conjugate
transport activities by ScYCF1 represent phenotypes whose
alterations can be investigated without too much experimental
eﬀort. Therefore, yeast has been used to translate mutations
occurring as natural variations, e.g., in CFTR causing cystic
ﬁbrosis to ScYCF1 and other yeast ABC transporters.
Here, we summarize the knowledge of mutations in the se-
lected ABC transporters Pgp, CFTR, SUR, HsMRP1 and 2
and ScYCF1. We concentrated on these transporters as models
since they exhibit strongly diﬀerent catalytical properties (e.g.,
substrate speciﬁcity, mode of transport, transporter vs. chan-
nel, protein–protein interactions); yet – when compared to
other ABC transporter subfamilies – the major diﬀerence be-
tween the chosen transporters is the presence of the N-terminal
extension in TMD0 in some members of the ABCC-subfamily.
In contrast, the order of the TMDs and NBDs in the two-
dimensional-structure of the selected transporters is identical.
As a reﬂection of the medical importance of the human ABC
transporters discussed here and their extensive biochemical
investigation, the ﬁrst version of this review had more than
some 370 references. During preparation of the ﬁnal version
of this manuscript we had to take the decision to eliminate a
AB
Fig. 2. Multiple alignment of the amino acid sequences of the NBD1 (NBD1; A) and NBD2 (B) of HsMRP1 (Swiss-Prot entry P33527), HsMRP2
(Q92887), HsCFTR (P13569), HsSUR1 (Q09428) and ScYCF1 (P39109). The Walker A and B motifs as well as the ABC signature are indicated and
in bold letters. The two letters preceding the protein abbreviations describe the organism from which the sequences were derived (Hs, Homo sapiens;
Sc, Saccharomyces cerevisiae). The diﬀerent sequences have been submitted to a multiple alignment using the Clustal W software from http://
bioweb.pasteur.fr. The following three characters are used to highlight conserved amino acids: ‘*’ indicates full identity of the amino acid at the
indicated position; ‘:’ indicates that one of the following ‘strong’ groups is fully conserved (STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF,
HY, FYW); ‘.’ indicates that one of the following ‘weaker’ groups is fully conserved (CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK,
NDEQHK, NEQHRK, FVLIM, HFY).
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Due to their medical importance, CFTR, SUR, the MRPs or
Pgp but also further human ABC transporters associated with
diseases have become important models to study the function
of these transporters. The identiﬁcation of disease-causing
mutations in combination with biochemical analysis of indi-
vidual variants demonstrates that single amino acid changes
many of which have been detected in the two NBDs are suﬃ-
cient to drastically alter function, expression or localization of
ABC transporters. A large number of naturally occurringpolymorphisms, mainly single nucleotide polymorphisms
(SNPs), has been reported for the MRP-related ABC proteins
including CFTR and was recently reviewed comprehensively
by Conseil et al. [42]. The Cystic Fibrosis Mutation Database
(http://www.genet.sickkids.on.ca/cftr/) presently lists more
than 1400 polymorphisms in the human CFTR gene. More
than 400 and 50 unique mutations in the ABCD1 gene or
the KATP channel complex are associated with X-linked
Adrenoleukodystrophy (X-linked Adrenoleukodystrophy
Database at http://www.x-ald.nl/) or persistent hyperinsuline-
mic hypoglycemia of infancy, respectively [29]. In many cases,
A. Frelet, M. Klein / FEBS Letters 580 (2006) 1064–1084 1067disease-causing mutations can be classiﬁed in categories such
as loss of transport or ATP hydrolysis function, structural
changes, changes in expression or stability, traﬃcking and
localization defects or disturbed protein–protein interactions
(e.g., for SUR1). Although the individual functional conse-
quences of SNPs still need to be investigated in detail and
screening of diﬀerent ethnical populations is ongoing it is evi-
dent that naturally occurring disease-causing mutations have
been instrumental in directing the choice of residues for site-di-
rected mutagenesis in many cases. Furthermore, mutations
identiﬁed in natural variants have been used to translate
changes in between ABC transporters (e.g., from CFTR to
ScYCF1 or SUR1 to SUR2 – see below). Thus, in view of
the large size of ABC proteins and the possibility to identify
variants due to disease-related phenotypic diﬀerences natural
variation is becoming a key resource in ABC transporter re-
search and – apart from clinical relevance – stresses the impor-
tance of diﬀerent ABC transporters as models for functional
studies.2. NBD mutations
The Walker A motif forms a loop that binds to the a- and c-
phosphates of di- and tri-nucleotides and is essential for ATP
hydrolysis. The Walker B may help to coordinate the Mg2+
ion, possibly through a water molecule or polarize the attack-
ing water molecule and is required for ATP binding [43]. The
ABC signature may be a c-phosphate sensor in the opposing
molecule of the dimer [43] and/or signal to the membrane-
spanning domains [10]. Other authors suggested a role in cou-
pling ATP hydrolysis to transport [3,44].
2.1. Walker motifs
2.1.1. Walker A.2.1.1.1CFTR. CFTR is composed of two
TMDs, two NBDs and the regulatory R domain. The contri-
butions of each domain have been demonstrated in studies
of wild-type and variants containing site-directed mutations
and with many agents that alter its function. The TMDs con-
tribute to the formation of the Cl selective pore [18,45–50],
the NBDs bind and hydrolyze ATP to regulate channel gating
[19,21,51–53] and phosphorylation of the R domain controls
channel activity [54–58]. Zerhusen and Ma [59] suggested that
NBD2 could have inhibitory and stimulatory roles in CFTR
activity by interaction with NBD1 directly or indirectly via
the R domain.
Two mutations, K464A (NBD1) and K1250A (NBD2) re-
duced ATP binding and hydrolysis [60–64]. K1250A abolished
ATP hydrolysis by disrupting the catalytic activity because its
position is in the P loop that forms the core of the ATP-bind-
ing pocket. In contrast, K464A led singly to a reduced overall
hydrolytic activity [61,62,65]. There is also a higher nucleotide-
binding aﬃnity at NBD1 than at NBD2 [61,66]. The conse-
quences of NBD mutations for channel gating are asymmetric.
Indeed, K1250A dramatically prolonged burst duration, sug-
gesting that hydrolysis at NBD2 might be coupled to burst ter-
mination [52,65,67], whereas K464A slowed channel opening
to a burst, suggesting that NBD1 might be a site of ATP inter-
actions governing opening [68]. More recent studies have sug-
gested that NBD1 might be involved in controlling burst
duration by closing the channel in a nucleotide-dependent
manner [69] and that NBD2 was implicated in both openingand closing mechanisms [52]. Vergani et al. [64] demonstrated
that ATP must bind at both catalytic sites before a channel can
open, and that the integrity of NBD1 Walker A motif, and
nucleotide bound there, inﬂuences the rate of exit from the
locked-open burst states. In conclusion, NBD1 ‘opens’ and
NBD2 ‘closes’ the CFTR chloride channel [19,64,68,70]. Apart
from this, Berger et al. [71] have demonstrated that, when
mutating K1250, ﬂuoride interacted with CFTR via NBD2
and slowed the rate of channel closure.
Cotten and Welsh [70] introduced a cysteine residue into a
non-conserved site of each NBD (residues A462 and S1248).
Subsequent N-ethylmaleimide (NEM) modiﬁcation of either
Walker A motif partially inhibited channel activity by decreas-
ing opening rate suggesting that inhibition by NEM modiﬁca-
tion was due to reduced ATP binding.2.1.1.2. Others. In several other ABC proteins, mutations of
the Walker A lysine or Walker B aspartate in either NBD abol-
ish both ATP hydrolysis and substrate transport [72].
2.1.1.3. SUR. K719A (NBD1 of SUR1) prevents ATP bind-
ing at both NBDs [73] and interferes with the stimulatory eﬀect
of KATP channel regulators which act through NBD2 [74–77].
Binding of MgADP at NBD2 promotes the stabilization of
ATP at NBD1, indicating cooperative nucleotide binding at
both NBDs [73,78–80]. In NBD2, K1348M (SUR2B) and
K1384A (SUR1) reduced ADP binding [81]. K1348M
(SUR2A) resulted in decreased ATPase activity, abolished
channel activation by ADP and produced channels with in-
creased sensitivity to ATP [76,82]. The corresponding lysine-
to-methionine mutation abolished the activatory eﬀects of
ADP in SUR1 [76]. ATP hydrolysis occurs at NBD2 while
NBD1 has only limited catalytic activity [78,79,82]. Discrete
conformations driven by the intrinsic ATPase cycle have been
identiﬁed to be essential for channel gating [83]. Individual or
combined mutagenesis of K719 and K1385 of SUR1 abolished
channel activation by both MgATP and MgADP [74]. In
SUR2A, binding of ATP at NBD1 is proposed to stabilize
the MgADP-bound state in NBD2. Indeed, an intact NBD1
is mandatory for NBD2-ATPase-dependent KATP channel gat-
ing. Stabilization of ATP at NBD1 depends on, and simulta-
neously promotes, engagement of NBD2 into an MgADP-
bound conformation required to counteract ATP-induced pore
closure [84]. By mutating K708 (NBD1), it has been suggested
that this residue precludes ATP binding to SUR1 [73]. In
SUR2B, K711R or K1352R eliminated ATP activation of
KCOs (potassium channel openers) binding, suggesting that
this binding requires a conformational change induced by
ATP hydrolysis in both NBDs [85]. In SUR2B, mutation
R1344A caused a large reduction of ADP-induced channel
activation as that of mutating K1348 to methionine. There-
fore, R1344 may be somehow functionally involved in the con-
trol of ADP binding [86].
Rainbow et al. [87] identiﬁed a region in the C-terminal do-
main of SUR2A, between residues 1294 and 1358, whose direct
interaction with full-length Kir6.2 is crucial for the assembly of
functional KATP channels. R1353H mutation (SUR1) partially
impaired ATP-dependent potassium channel function [88].
Mikhailov and Ashcroft proposed that NBD1 was critical
for SUR assembly and precised that TM12 took part in
SUR1 Kir6.2 interaction [89].
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diminished nucleotide-binding abilities. Both mutations de-
creased the transport of LTC4 by approximatively 70% or to-
tally, respectively [90]. NBD1 and NBD2 allosterically aﬀect
each other [90,91]. The C682A (NBD1) mutation decreased
the Kd value for ATP indicating increased aﬃnity for this
nucleotide while A1331C (NBD2) did not have any eﬀect, sug-
gesting that ATP binding at NBD1 at low concentration
played a more important regulatory role than the binding at
high ATP concentration and that ATP hydrolysis at NBD2
played a dominant role in the ATP-dependent LTC4 transport
[92].
2.1.1.5. P-glycoprotein. Azzaria et al. [4] mutagenized glycine
and lysine residue at the position 431 and 1073 and positions
432 and 1074, respectively, in NBD1 and NBD2 of mouse
MDR1 and demonstrated that ATP binding was impaired in
the mutants. Mutation of the lysine residue in either NBD
abolished both ATPase activities of MDR1 protein [93]. Both
NBDs of MDR1 function in a cooperative manner with re-
spect to ATP hydrolysis [6]. Via mutagenesis of C431 and
C1074 in human MDR1 Urbatsch et al. [94] showed that these
cysteines are responsible for inhibitory disulﬁde cross-linking
between the two NBDs. Mutations K429R (NBD1) and
K1072R (NBD2) of MDR3 completely abolished Pgp-medi-
ated drug-resistance and drug-transport [7]. S430A and/or
S1073A/T changes in the catalytic sites of MDR3 abolished
MgATPase and transition state formation at both sites [95].
2.1.2. Walker B.2.1.2.1CFTR. D572N resulted in a marked
decrease in sensitivity to channel activation while D1370N re-
sulted in an increase in sensitivity [60,96]. D1370 coordinated
the catalytic Mg2+ in NBDs [96]. Mutations of D572 and
D1370 abolished ATPase and adenylate kinase activity eﬀects
on channel gating [63,64].
2.1.2.2. SUR. It was suggested that glutamate acted as a key
hydrolytic residue in NBD2 of the bacterial MJ0796 ABC
whose structure has been resolved by crystallization [97]. The
model described by Campbell et al. [98] suggested that muta-
tion E1506 (NBD2) in SUR1 to aspartate reduces ATP hydro-
lysis, whereas D854E (NBD1) enhances the hydrolytic activity.
Mutation of D854 (NBD1) and D1506 (NBD2) of SUR1 abol-
ished channel activation by MgADP [28,74,75] and mutations
in NBD1 abolished ATP binding [73]. In SUR2A, D1469N
(NBD2) abolished channel activation by ADP [76] and muta-
tions of D1470 (NBD2) disrupted ATP hydrolysis and im-
paired response to nicorandril [9,82,99].
2.1.2.3. HsMRP1. D792A (NBD1) and D1454L/E1455L
(NBD2) diminished nucleotide-binding abilities rather than
completely abolishing binding [100]. The variant D792L was
unable to mature conformationally and D792A led to an accu-
mulation of equal amounts of mature and immature proteins
but still resulted in defective nucleotide interaction and organic
anion transport, indicating that nucleotide hydrolysis at NBD1
was essential for MRP1 function [101].2.1.2.4. P-glycoprotein. ATPase activity was fully inhibited
when only one NBD was photolabeled [102]. But Hrycyna
et al. [9] reported that the mutations D555N and D1200N
(D555 and D1200 are presumably involved in Mg2+ binding)resulted in impaired nucleotide photoaﬃnity labeling only
for D555N. Both mutations did not aﬀect the ability of the
transporter to bind substrate but completely abrogated trans-
port function and both basal and drug-stimulated ATPase
activity. This suggested that the two NBDs randomly hydro-
lyzed ATP, but displayed obligatory catalytic cooperativity
[102] such that inhibition of ATP hydrolysis at one catalytic
site prevented even a single hydrolysis event at the other [7].
The implied functional similarity between the two NBDs cor-
responded to their substantial sequence identity, and was cor-
roborated by the ﬁnding that mutant Pgp with a second copy
of NBD1 in place of NBD2 could still extrude drug from cells.
All these data suggest that (i) the two NBDs are asymmetri-
cally acting but linked; (ii) that a conformational change in
the protein might occur upon ATP hydrolysis; (iii) that bind-
ing of ATP at one site aﬀected hydrolysis at the other [9].
Urbatsch et al. [8] showed the importance of the highly con-
served putative catalytic carboxylate residues E552 (NBD1)
and E1197 (NBD2) in mouse MDR3, possibly involved in ini-
tiation or in other aspects of catalysis. These homolog residues
immediately followed D551 and D1196 which coordinate
Mg2+ at each site; D551N and D1196N caused diﬀerent con-
formational changes as measured by trypsin sensitivity [103].
Mutations of D551 or D1196 completely abolished Pgp-medi-
ated drug-resistance and drug-transport [7,9].
Later studies indicated that the mutants E552Q and
E1197Q induced asymmetric conformations of the two NBDs
[104]. The mutants displayed very low ATPase activity with
an asymmetric behavior (E552Q having 2.6 times higher
ATPase activity compared to E1197Q) and inability to form
the normal transition state. The mutations impaired rapid for-
mation of the NBD dimer interface that normally occurs
upon ATP binding and/or distort that interface during forma-
tion of altering characteristics of the closed conformation in
which the transition state normally forms. They interfered
with the formation of the correct interdigitated NBD dimer
interface, necessary to generate the closed conformation,
which follows upon ATP binding and progress to formation
of the normal transition state. Double mutation E552/E1197
arrested the enzyme in a conformation, likely a stabilized
NBD dimer, which occluded the nucleotide, showed preferen-
tial binding of ATP, did not progress to a normal vanadate-
sensible transition state but hydrolyzed ATP and released
ADP slowly and was still capable of tight binding of 8-azi-
do-ADP. Impairment of turnover was primarily due to the
inability to form the normal transition state rather than to
slow ADP release. Usually, the occluded nucleotide confor-
mation occurred transiently after MgATP binds to both
NBDs with associated dimerization, and before progression
to the transition state [34].
Sauna et al. [105] studied the equivalent conserved gluta-
mates in human MDR1, introducing glutamine and alanine
mutations. Consistent with the earlier data, both drug-trans-
port and ATPase activity were strongly impaired in mutant
proteins and vanadate-induced trapping of 8-azido-ADP was
observed. The interpretation of the human MDR1 mutation
diﬀered from Urbatsch et al. [8] because Sauna et al. [105]
concluded that a second round of ATP hydrolysis, required to
reset the drug-binding sites after an initial outward transport-
generating ATPase turn-over, was blocked. Sauna et al. [105]
also found that when glutamine or alanine mutations were
introduced simultaneously into both NBDs, the resultant dou-
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do-ADP upon incubation with 8-azido- ATP along with loss
of ATPase and drug-transport activities.
2.1.2.5. YCF1. The D777N (NBD1) mutation aﬀecting the
ﬁrst aspartate residue in the Walker B motif exhibited a
strong defect in the apparent aﬃnity for ATP and Vmax
of transport; this residue may be involved in coupling ATP-
ase activity to substrate binding and/or transport across the
membrane [106]. Thirteen intragenic second-site suppressors
were identiﬁed for D777N. Two of the suppressor muta-
tions were located in TMD1 and nine were found within
TMD2. Furthermore, one suppressor mutation each was
found in NBD1 and NBD2. The results suggested that
NBD1 is in close physical contact with the other domains
and that the eﬀect of the suppressor mutations did not sim-
ply restore defective catalytical ATP hydrolysis activities of
D777N/NBD1 but rather altered substrate speciﬁcity of
YCF1. It will be interesting to learn from structural inves-
tigation of MRPs to what extent ATP hydrolysis coordi-
nated by the Walker B aﬀects the transport eﬃciency
across the pore.
2.2. Mutations in the ABC signature
Previous reports described mutations of the serine residue in
LSGGQ. It is known that cystic ﬁbrosis patients show muta-
tions of serine to asparagine, isoleucine or arginine [107] and
that the corresponding S507 mutation introduced into the
yeast ABC transporter STE6 caused substantial defects in
transport function but not changes in abundance or localiza-
tion [108]. In the bacterial transporter HisP, mutation of serine
to phenylalanine strongly reduced the transport activity,
although photolabeling of the catalytic sites was reduced by
only 50% [44]. All of these reported mutations signiﬁcantly al-
ter the bulk and chemical nature at the position of the Ser res-
idue. In Pgp, it was reported that single serine to cysteine
mutations in NBD1 or NBD2 of human MDR1 caused partial
loss of ATPase activity [109].
2.2.1. CFTR. A cysteine instead of a serine in the LSGGQ
motif in either NBD1 (S549C) or NBD2 (S1347C) inhibited
CFTR channel activity [70]. Naturally occurring mutations
at the glycine residue preceding the glutamine, G551 (NBD1)
and G1349 (NBD2), are associated with CF disease [19]. In
such mutants, channel rate opening and ATPase rate were
both markedly reduced. G551D is known to alter channel
activity without aﬀecting its traﬃcking, to reduce nucleotide
binding and ATPase activity of NBD1 [60,110,111]. Mutations
of G551 or G1349 produced similar reductions in the sensitiv-
ity to activating conditions [96]. G551 is an important molec-
ular site for inhibition by high concentration of genistein but
G1349 is a major site for activation by low concentration of
genistein. Both mutations alter speciﬁcally the mechanism of
CFTR channel activation by genistein suggesting that the sig-
nature sequences should act as molecular switches that upon
interaction with genistein turn on and oﬀ the channel [112].
Genistein chemically complemented the defective function of
G551D [113].
Based on sequence similarity between CFTR and GTP-bind-
ing proteins in the LSGGQ motif, Carson and Welsh [68] pre-
dicted that the terminal residue in the LSGGQ motif may
correspond to a highly conserved glutamine residue in GTP-binding proteins that directly catalyses the GTPase reaction.
Mutations of this residue in either NBD1 or NBD2 which were
predicted to increase or decrease the rate of hydrolysis altered
the duration of channel open and closed states in a speciﬁc
manner without altering ion conductance or ADP-dependent
inhibition. They speculated that the rates of ATP hydrolysis
at NBD1 and NBD2 determine the duration of the closed
and open states of the channel, as the rate of GTP hydrolysis
by GTP-binding proteins determines the duration of their ac-
tive state. Sheppard and Welsh [21] proposed two models for
the action of the two NBDs in ATP hydrolysis and the eﬀects
of the diﬀerent mutations. Q552H (NBD1) slowed CFTR
channel opening without aﬀecting closing, whereas the con-
verse mutation, H1350Q (NBD2) accelerated channel closing
without inﬂuencing the channel opening rate [68].
2.2.2. SUR. Mutation of S830 or S1482 (SUR1) to argi-
nine did not aﬀect nucleotide binding. Mutations at S830 re-
duced and at S1482 abolished KATP channel activation by
MgADP, indicating that this serine might be implicated in
transduction of nucleotide binding into channel activation
and showing again that there is an asymmetry between the
two NBDs [114]. Other mutations such as G1479D, G1479R,
G1485D, G1485R, Q1486H all abolished stimulation by
MgADP and diazoxide [75].
2.2.3. HsMRP1. The glycines in the fourth position of the
LSGGQ motifs have been mutated into aspartic acids (G771D
and G1433D). The glycine to aspartic acid and also leucine to
arginine replacements resulted in complete loss of both the
ATPase and the transport activities. These residues should
therefore be part of the conformational network, which is
responsible for the accelerated hydrolytic activity upon inter-
action of the protein with its transported substrates
[90,115,116].
2.2.4. P-glycoprotein. In MDR1, the drug interaction sites
have been reported to lie in the TMDs [117,118]. However,
some mutations in the ABC signature such as G534D and
I541R abolished drug-stimulated ATPase activity. G534V
and L531R practically eliminated MDR1 expression [119].
The functional roles of the two ABC signature sequences
‘‘LSGGQ’’ were studied by mutating serine to alanine. In
mouse MDR3 the two relevant residues are S528 (NBD1)
and S1173 (NBD2). Mouse MDR3 displays 87% of sequence
identity to human MDR1. S528A and S1173A each reduced
ATPase activity by 26%, and showed generally symmetrical ef-
fects on function, consistent with equivalent mechanistic roles
of the two nucleotide sites. Synergy between the two mutations
when combined was remarkable and resulted in strong cata-
lytic impairment. The serine residues were not involved signif-
icantly in MgATP- or MgADP-binding or in interdomain
communication between catalytic sites and drug-binding sites.
Retention of the hydrolytic product MgADP is not the cause
of reduced turnover. Mutation of serine to alanine reduced
the strength of interaction with the chemical transition state
speciﬁcally, as shown by vanadate–ADP and beryllium ﬂuo-
ride–ADP trapping experiments. Therefore the two conserved
serine residues cooperatively accelerated ATP hydrolysis via
chemical transition state interaction. Because the transition
state complex is currently believed to form in the dimerized
state of the NBD, one may also conclude that both serine hy-
droxy-groups are necessary for correct formation of the dimer
state [35].
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signature: F508 in CFTR and corresponding phenylalanines
in other ABC transporters
Apart from the Walker A and B motifs as well as the
ABC signature (LSGGQ), further amino acids within the
NBDs appear to be of functional signiﬁcance for ABC trans-
porters. In this chapter, the eﬀects of the DF508 deletion
mutation in CFTR are discussed. SUR1 and some of the hu-
man and yeast MRPs contain phenylalanines in the NBDs
that like F508 of CFTR cause traﬃcking defects when de-
leted. The eﬀects of mutations in phenylalanine residues of
NBDs are summarized in Fig. 3. Fig. 4 lists mutations in
further amino acids of NBDs leading to defects in ABC
transporter functions.
The most common CF-causing mutation (66% of all cases)
is the DF508 deletion which aﬀects the folding (absence of
glycosylation) and transit of the protein, resulting in
premature degradation of the channel via the ubiquitin–
proteasome pathway at the endoplasmic reticulum (ER)
[53,120–122], probably owing to its temperature-sensitive
folding defect [123]. Indeed F508 provides hydrophobic con-
tacts for domain–domain interactions that are indispensable
for the post-translational folding of NBD2 and for stabiliza-
tion of the native channel [124,125]. The DF508 CFTR mis-
processing is overcome by chemical chaperones, reduced
temperature and small molecules such as genistein [126] or
quinazoline derivatives [127], which partially restore the cell
surface channel function [128]. In addition, the mutant
protein can be rescued to the plasma membrane by Rab11
overexpression, proteasome inhibitors or inhibition of
Rab5-dependent endocytosis [129]. Indeed, DF508 decreases
the structural stability of the P26 peptide a-helix encompass-
ing residues 498–523 in NBD1, as well as that of the b-sheet
formed by the P67 peptide (residues 450–516) [130]. Wang
et al. [131] demonstrated that its deletion caused also atten-
uated phosphorylation-dependent activation of CFTR chlo-
ride channel. Recently, Tsigelny et al. [132] have identiﬁed
molecular determinants that modulate traﬃcking of DF508
CFTR.Transporter  Aa  Effect of deletion 
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3.1. YCF1
Based on the cadmium sensitivity of the S908A mutant,
S908, corresponding to serine in the R domain of CFTR was
suggested to be a site of protein kinase A (PKA) phosphoryla-
tion [37]. By mutation of this serine into alanine, aspartate and
glutamate Eraso et al. [149] have concluded that the phosphor-
ylation of S908 was necessary for transport activity of glutathi-
one conjugates into vacuolar membrane vesicles and suggested
that PKA was not the kinase responsible for this phosphoryla-
tion. Furthermore, mutation of T911 into alanine or aspartic
acid suggested that its phosphorylation was also required for
cadmium detoxiﬁcation and transport activity, pointing to
the involvement of another kinase in the regulation of the pro-
tein by phosphorylation.
The cytoplasmic loop (CL) 6 has been shown to be necessary
and suﬃcient for proteolytic cleavage and regulate substrate
speciﬁcity since certain mutations in this region lower cellular
cadmium resistance with a concomitant gain in arsenite resis-
tance [150].
3.2. CFTR
The R domain, once phosphorylated, stimulates the ATPase
activity and channel gating by a mechanism that is consistent
with increased binding of ATP. It possesses multiple potential
sites for phosphorylation by PKA and protein kinase C
(PKC). Indeed, phosphorylation of CFTR by PKA is a neces-
sary but not suﬃcient condition for channels to gate; once
phosphorylated, channels require exposure to MgATP to open
and close [19,21]. Of CFTR’s many consensus sites for phos-
phorylation by PKA, to date ﬁve serines (S660, 700, 737, 795
and 813) have been shown to be phosphorylated in vivo
[151] and eight (those ﬁve plus S712, 753 and 768) in vitro
[152]. S768 seems to be the most readily phosphorylated serine
in the isolated R domain in vitro. Its phosphorylation inhibits
activity of CFTR at low and high concentrations of PKA
[153]. Mutations of serine residues available for potential
PKA-phosphorylation have been shown to aﬀect domain con-  Experimental system Ref.
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Fig. 4. Eﬀects of single amino acid changes in the NBDs outside of the Walker sequences and the ABC signature. Relative positions of the discussed
mutations within the NBDs are given by small cartoons. Yellow and green background indicate mutations in NBD1 or NBD2, respectively. The
position of the mutation relative to the Walker A (A), B (B) sequences and the ABC signature (ABC) are indicated as red or blue circles. CC, channel
closing; CO, channel opening; PC, patch clamp; SDM, site-directed mutagenesis; Tf, transfection (see [137–148]).
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S753, S768, S795, S813 strongly aﬀects channel activity
[19,54,56–58,155], although partial activation persists after
PKA sites are removed in various combinations, and no single
site seems to be essential [54,156]. At least in the case of S660,
phosphorylation at one site alone is suﬃcient for regulation of
Cl channel activity.
Channel responses to PKA are increased by exposing
whole-cell or inside-out patches to puriﬁed PKC. PKC phos-
phorylation has been demonstrated at S686 and S790 [151].
Direct phosphorylation of CFTR at one of these residues
(T582, T604, S641, T682, S686, S707, S790, T791 and
S809) of PKC consensus sequences is required for both the
partial activation by PKC and for its modulation of CFTRresponses to PKA [157]. T582, T604 (both in NBD1) and
S686 were found to be essential for PKA activation [158].
NBD2 seems to have a role in the mediation of the PKC
potentiation eﬀect [159]. The N terminal part participates
in ATP-dependent channel gating. I601F, L610S, A613T,
D614G, I618T, L619S, H620P, G628R and L633P resulted
in aberrant processing. G622D and R792G have reduced
intrinsic chloride channel activities whereas H620Q and
A800G resulted in increased intrinsic chloride transport
properties [160]. L619S resulted in an inactive channel
whereas D614G and I618T display a partial activity as chlo-
ride channels [161].
Mutation of P740, 750 and 759 to alanine activated the
channel by increasing the number of openings and not the
1072 A. Frelet, M. Klein / FEBS Letters 580 (2006) 1064–1084open time [162]. Furthermore, Xie et al. [163] have demon-
strated the role of a region between amino acids 817 and 838
in channel function. Its deletion eliminates completely PKA
dependence of channel activity. They speculated that this re-
gion interacts with other cytosolic domains to control opening
and closing transitions. When C832 was mutated to alanine,
CFTR failed to respond to NEM and this covalent modiﬁca-
tion can also stimulate CFTR irreversibly [164]. E822KFig. 5. Schematic representation of the eﬀects of non-NBD mutations in
functionality of CFTR (A), SUR (B) and HsMRP1 (C). (B) If not stated othe
cases, comparable regions important for substrate recognition, transport actand E826K reduced channel conductance and opening
[160,165].
3.2.1. Non-R-domain mutations. An overview of the eﬀects
of mutations outside the cytosolic NBDs on CFTR, SUR and
HsMRP1 is illustrated in Fig. 5. A cluster of negatively
charged residues in a putative helical region of the amino ter-
minal tail (N-tail) participates to CFTR channel gating. Ala-
nine substitutions at these positions (D47, E51, E54 andnatural variants and site-directed mutants on diﬀerent aspects of the
rwise, comparable eﬀects were reported for SUR1 and 2. (C) In several
ivity and traﬃcking have also been identiﬁed in HsMRP2 (see text).
A. Frelet, M. Klein / FEBS Letters 580 (2006) 1064–1084 1073D58) resulted in accelerated deactivation kinetics in intact oo-
cytes and shortened open channel bursts in excised membrane
patches. They destabilized channel opening apparently by
aﬀecting a gating transition that is downstream of channel acti-
vation by phosphorylation and ATP binding [166]. Fu and
Kirk [167] demonstrated that the N-terminus of CFTR modu-
lates both the rates of channel opening and closing suggesting
that the negative charges at residues E54 and D58 are impor-
tant for duration of channel opening.
To identify residues that line the CFTR pore, Akabas et al.
[47,168] used the substituted cysteine accessibility method. At
the extracellular end of TM1 between G91 and P99, G91,
K95 and Q98 have been identiﬁed to line the pore, suggesting
that between G91 and Q98, TM1 has an a-helical secondary
structure and that this region of the channel plays a signiﬁcant
role in determining the chloride conductance. G85E and G91R
aﬀected folding by insertion of a charged residue within the
plane of the bilayer [169]. Mutations in prolines P99 (TM1)
and 205 (TM3) are associated with cystic ﬁbrosis. P99 plays
an important structural role by linking a-helices and contrib-
utes to the formation of the pore; P205 is critical for correct
protein processing [170].
Mutation of K95 (TM1) altered the permeability and/or
conductance ratios for halides [18]. R117H, a mutation associ-
ated with mild clinical disease, displayed altered single-channel
properties and a reduction in open probability [45].
CFTR contains positively charged amino acids within the
putative transmembrane (TM) sequences (K95 (TM1), R134
(TM2) and R1030 (TM10); [171]). These residues are con-
served across species and they may have an important func-
tional role. K95D altered the whole cell anion permeability
sequence by converting CFTR from a low to a high iodide per-
meability pore [18]. These data suggest that K95 partially
determines the anion selectivity and permeation in the pore
[18] and lies towards the extracellular surface of the channel
[171]. R1030E did not alter the anion permeability sequence
although PI/PCl values were increased [18]. H139R, G149R,
D192G and R258G in the two ﬁrst CLs inhibited maturation
and transport of CFTR to the cell surface. G178R and
E193K reduced anion translocation capability [172].
The C225R mutant exhibits cAMP-dependent chloride
ﬂuxes while the protein is poorly expressed but fully glycosyl-
ated. Using synthetic peptides corresponding to TM4, this res-
idue together with D232 and Q237 have been shown to
mediate helix–helix interactions [173]. Other endogenous cys-
teine residues located within the NBDs and/or R domain gov-
ern channel gating by speciﬁcally modulating open probability
[174]. Mutating G314 and V317 (TM5) and S1118 (TM11) af-
fected both anion permeation and channel gating, suggesting
that they also contribute to the pore [50,175,176]. On the basis
of the homologous positions occupied by TM6 and TM12 in
the amino and carboxy terminal halves of the CFTR molecule
and the similar and important roles played by TM6 and TM12
in Pgp (see below), it has been suggested that TM12, like TM6,
may play a role in forming the pore and determining its func-
tional properties [46,177]. Gupta et al. [178] have examined the
eﬀect of T1134A, M1137A, N1138A, S1141A and T1142A and
found that, in contrast to those in TM6, mutations in TM12
have little eﬀect on channel permeation properties, suggesting
that TM6 and TM12 make highly asymmetric contributions
to the pore. N1138A and T1142A signiﬁcantly blocked the
channel by indirectly reducing interaction between Cl ionsand glibenclamide within the pore [179]. M1137R interfered
with the proper maturation of the protein and the whole cell
cAMP activated chloride currents were reduced for M1137V,
I1139V, D1152H and D1154G, indicating that these mutations
interfere with the proper gating of chloride channels [180]. The
intracellular loop 4 seems to be important for the structure and
function of CFTR. When a glycosylation site was introduced
at V1056, the amount of protein decreased. When R1066
was mutated into R1066C, the protein was not correctly pro-
cessed, not fully glycosylated, reﬂecting a defect in protein bio-
synthesis and little discernible eﬀect on function; in contrast,
mutant F1052V was processed normally but had dramatically
altered function [181,182]. The COOH-terminal end appears to
be important for traﬃcking because it contains a PDZ motif
essential but not suﬃcient for localization of the C terminus
to the apical membrane [183]. Mutation of the dileucine motif
L1430–L1431, as well as Y1424 and I1427 increased the
amount at the cell surface and mutation of F1413 revealed that
it was indispensable for the native structure [184,185].
3.2.2. TM6 region. Mutations of speciﬁc residues in TM1,
TM5, TM6 and TM12 altered conductance, permeation and
the locking of open channels. These TM segments appear to
line the CFTR pore [18,45–47,50,186]. Structure–function
investigations of the Cl channel have focused on the sixth
TM region (TM6) and there is a strong evidence that it plays
a central role in forming the pore and determining its func-
tional properties [18,45–50,177,178,186–191]. Mutations alter
anion selectivity [18,49,187,189–191], conductance [45,46,186,
187,190,192], multi-ion pore behavior [186] as well as the bind-
ing of permeant [50,190,191] and blocking anions [46,179,193].
Mutations have been performed on residues in the central por-
tion: at R334 [45], at K335 [18,50,186], F337 [189–191], T338
[187,190,191], S341 [46,191], R347 [48,186] and R352 [188].
11 residues between K329 and Q353 likely line the CFTR pore
(I331, L333, R334, K335, F337, S341, I344, R347, T351, R352
and Q353) [47,168]. Most of the secondary structure of TM6 is
probably a-helical but at the intracellular end of the segment,
including R352, it may form a pore loop that contributes to the
anion selectivity of the pore.
R334, K335, S341 and R347 may directly or indirectly con-
tribute to the control of Cl permeation [18,45,46,186]. They
are positively charged amino acids [171], conserved across spe-
cies and associated with CF: R334Q/W and R347C/H/L/P.
K335E altered the whole cell anion permeability sequence by
converting CFTR from a low to a high I permeability pore.
These data suggest that K335 partially determines the anion
selectivity. Mutation of K335 and R347 altered also the perme-
ability and/or conductance ratios for halides [18]. R334W and
R347P associated with mild clinical disease displayed altered
single-channel properties [45]. Tabcharani et al. [186] suggested
that, as anions pass through the CFTR pore, they interact with
the positive charge at R347 and mutations at R347 disrupted
function by converting the channel from a multi-ion to a sin-
gle-ion pore. R347E had little or no eﬀect on the halide perme-
ability or conductance sequences [18]. In contrast, K335E
changed the halide permeability and/or conductance sequences
[18] but did not alter the anomalous mole-fraction eﬀects [186].
R347D altered GSH inhibition and reduced ATPase activity
by decreasing nucleotide turnover rather than aﬃnity [194].
Anion selectivity is predominantly controlled by a single site
involving adjacent residues F337 and T338 and modiﬁed by
anion binding to ﬂanking sites involving the more extracellular
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utes to a narrow region of the pore where permeating Cl ions
interact most strongly with residues lining the walls of the
pore. Alanine substitutions of these residues has been shown
to strongly aﬀect conductance, which is greatly reduced in
F337A [190] and S341A [46] and signiﬁcantly increased in
T338A [187]. Mutations of F337 and T338 strongly changed
permeability sequence [187,189,190,196] suggesting that anion
selectivity was determined primarily at a localized pore region
close to these residues. They signiﬁcantly weakened the gliben-
clamide block [179] while mutagenesis of S341 and R347 [197]
had minimal eﬀects on channel blocking by glibenclamide.
T338 within the anion conduction pore senses a positive elec-
trostatic potential in the pore probably due to R334 or other
residues near this position [192,198]. The positively charged
amino acid residue, R334, predicted to lie in the outer vestibule
of the pore [47,191,192] makes a major contribution to anion
binding and permeation within the pore and possesses a unique
ability to coordinate ion-ion interactions at this site in the pore
[48,187,189,196]. T339 may also play an important role in
determining the anion selectivity. Mutating K335 to a nega-
tively charged glutamate reduced conductance by about 50%
[18,186]. Covalent modiﬁcation of cysteines substituted at
R334 or K335 with the negatively charged methanethiosulfo-
nate reagent MTSES caused a similar decrease, whereas mod-
iﬁcation by positively charged reagents had the opposite eﬀect
[192]. L346P destabilized the local hydrophobic character and
therefore was suﬃcient for marking CFTR as a non-native
protein to the ER quality control, with accompanying deleteri-
ous consequences to global protein folding events [199].
R347 is important for pore architecture because it forms a
salt bridge with R924 that stabilizes the structure [200]. Clain
et al. [201] showed that R347H was associated with mild defec-
tive Cl channel activity and that D979A defect led to mispro-
cessing. D979, located in the third CL connecting TM8 and
TM9, is critical for processing and Cl channel activity. These
authors also demonstrated that the two mutations could act in
a concerted manner in cis to alter dramatically function con-
tributing to the wide variability of CF disease. R352 is ﬂanking
the predicted cytoplasmic end of TM6 and its positive charge
contributes to an electrostatic potential in the channel that
forms a barrier to cation permeation. Mutations of this residue
altered anion:cation selectivity [188].
3.3. SUR
Mutagenesis studies have demonstrated the presence of two
N-linked glycosylation sites on SUR1 at positions N10 and
N1050 corresponding to the N terminus and the external loop
following TM12 [202] (Fig. 5B). In many systems, glycosyla-
tion has been shown to play a role in surface expression and
as well as protein stability. Conti et al. [203] showed that muta-
tion of these residues led to a reduction of surface expression
of SUR1 due to an increased ER retention and suggested that
SUR1 glycosylation was a key element for proper traﬃcking
and surface expression of KATP channels. Similarity in se-
quences and conservation of N10 glycosylation site suggested
that it is likely that SUR2A and SUR2B would be inﬂuenced
by glycosylation in a similar manner to SUR1. In SUR1,
L1544P resulted in impaired function as well as ER retention
and displayed diminished glycosylation while R1394H resulted
in retention within the Golgi network associated with absence
of functional channels [204–206].Shyng et al. [204] have reported that H125Q, N188S, F591L,
T1139M, R1215Q and G1382S generated functional channels
in the absence of ATP, indicating that the lack or reduction
of KATP channel sensitivity to MgADP is a common molecular
defect associated with the disease. Wada et al. [207] have
reported that R656A (SUR2A) or R665A (SUR1) abolished
the Gbc2-dependent alteration of channel activities, Gbc2
being the subunits of the G proteins that modulate KATP chan-
nels.
SUR1 and SUR2 show inverse pharmalogical proﬁles:
SUR1 exhibits high aﬃnity for glibenclamide and low aﬃnity
for most KCOs whereas SUR2 shows lower aﬃnity for gliben-
clamide and high aﬃnity for KCOs [23,208]. The TMD2, espe-
cially the region between TM15 and TM16, is critical for
sulfonylurea binding [209]. SUR1 containing a serine at the
position 1237 has a higher aﬃnity compared to SUR2B which
possesses Y1206 at the corresponding place leading to reduced
blocking potential of sulfonylureas towards the Kir6.2/SUR1
channel [209]. By inserting the mutation Y1206S into SUR2B
the aﬃnity for and channel sensitivity towards glibenclamide
increased by a factor of 10–25 [210]. Y1206S mutations in
SUR2A and SUR2B showed also that the inhibitory eﬀects
of ATP and ADP on glibenclamide binding were diﬀerent from
one type to another [211]. Recently, Stephan et al. [212] dem-
onstrated that Y1206S has the same eﬀect in SUR2A com-
pared to SUR2B with regard to the increased aﬃnity
towards glibenclamide. Studies with chimeric proteins, trun-
cated proteins and point mutations suggest that sulfonylureas
interact with amino acid residues between TM5 and TM6
(CL3) and between TM15 and TM16 (CL8) [209,213].
TMD0 seemed not to be required for high-aﬃnity glibencla-
mide binding to SUR1 [213]. Alanine substitutions around
W232 identiﬁed a cluster of amino acids critical for aﬃnity
labeling [214]. The benzamido group of glibenclamide should
be positioned near this residue. Two TMD0 mutations,
A116P and V187P, abrogated the association of TMD0 and
Kir6.2. Indeed, these mutations prevent traﬃcking of KATP
channels from the ER to the plasma membrane and sulfonyl-
ureas function as chemical chaperones to rescue KATP channel
traﬃcking defects [215].
A detailed consideration of the available structure–activity
data suggested that SUR1 was able to accommodate the
lipophilic center adjacent to the anionic group on the sulfo-
nylurea moiety (i.e., the butyl side chain in tolbutamide or
the cyclohexyl ring in glibenclamide) while SUR2A was
not. These results imply that SUR1 has a hydrophobic cav-
ity able to accommodate these side chains and that this cav-
ity is missing or occluded in SUR2. Substitutions of S1237
with tyrosine, the analogous residue in SUR2, reduced the
aﬃnity of SUR1 for tolbutamide and glibenclamide [209].
One possibility is that S1237 was in close proximity to the
lipophilic center and that Y1206 occluded the binding in
SUR2A; the reverse substitution, Y1206S in SUR2B, in-
creased the aﬃnity for glibenclamide several fold but not
to the level of SUR1 [210].
In TM17, T1285 and M1290 (SUR1), or K1249 and T1253
(SUR2A), were reported to be important for the activation of
KATP channels by openers such as cromakalin analogs and ril-
makalim. Their mutations led to class-speciﬁc eﬀects on opener
binding by increasing opener aﬃnity or by changing allosteric
coupling between opener and glibenclamide binding [216].
Moreau et al. [217] reported that T1253 would permit activa-
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lix corresponding to TM17 in SUR1 has also been implicated
in binding of substrates in other polyspeciﬁc ABC transporters
such as MRP1 [218,219], MRP2 [220], MRP3 [221]. R1394H
or L1544P mutations (SUR1) have been shown to impair nor-
mal traﬃcking of the protein to the plasma membrane [208].
Finally, mutational analysis of the COOH-terminal residues
indicated that the dileucine motif (L1566) and a downstream
phenylalanine (F1574) residue formed important plasma mem-
brane-targeting signals [222].3.4. HsMRP1
Ito et al. [223] showed that Pro residues in TMD1 (P42, P51
and P104) and CL3 could play a role in the expression and
structure of the protein (Fig. 5C). Other residues in the NH2
proximal region (C43 and C265) were suggested to be impor-
tant for its structure and selected transport activities [224]. In
previous studies, it has been shown that an NH2-truncated pro-
tein lacking the ﬁrst 67 amino acids (MRP167–1531) did not
transport LTC4, which indicated that the region containing
the extracellular N-terminus and the ﬁrst TM helix was re-
quired for at least some aspects of transport function [225].
C7 was critical for structure and transport function [224]. On
the other hand, studies of other truncated mutants have shown
that MRP1 lacking the ﬁrst ﬁve TM helices (MRP1204–1531)
could bind and transport LTC4 at levels comparable to the full
length protein but display impaired traﬃcking to the plasma
membrane while MRP1 polypeptides with further deletions in
CL3 do not [225,226]. These ﬁndings suggest that TMD0 is
important for protein traﬃcking and that CL3 plays an impor-
tant role in substrate and inhibitor recognition and transport
[225,227]. The region of CL3 between amino acids 204 and
280 seems to be essential as well for substrate binding and
transport (LTC4 and GSH) as appropriate traﬃcking [226].
Charged amino acids (L332, H335 and D336) in TM6 are
critical determinants for substrate speciﬁcity and transport
activity. Mutation of L332 caused a selective loss of LTC4
and GSH transport whereas mutation of D336 eliminated or-
ganic anion transport activity [227]. Haimeur et al. [228] dem-
onstrated that L319, L347, proximal to TM6 seemed to
contribute selectively to GSH transport activity, that D430
was required for stable expression in mammalian cells. By
mutating D336 (TM6), L396 (TM7), D436 (TM8) and R593
(TM11), these authors also suggested that TMD2 charged res-
idues in or proximal to TMs 6, 7, 8 and 11 played critical but
diﬀerential roles in transport activity and substrate selectivity.
Serial mutations of proline residues veriﬁed the importance of
the abovementioned TM plus two other TM regions, TM10
and TM14 in transport function [229]. Other single amino
acids substitutions could dramatically and selectively alter
the substrate speciﬁcity [228,230]. Mutation of R433 into ser-
ine in the CL between TM7 and TM8 resulted in substrate-spe-
ciﬁc alterations of function [231]. F594A or substitution in
P595 resulted in a global loss of organic anion transport and
LTC4 binding [229,232]. This residue is suggested to partici-
pate to a carrier through which substrates are presumed to
be translocated involving also further tryptophane and tyro-
sine residues (W553 (TM10), W1198 (TM16), Y1243 (TM17)
and W1246 (TM17)). These residues have already been shown
to have the same eﬀect on transport activity as F594 when mu-
tated [228].R1197, R1202, E1204 and R1249 are important for expres-
sion and/or function [219,233]. Zhang et al. [234] have demon-
strated that R1084 (TM14) caused a substantial reduction in
E217G, LTC4 and GSH transport and drug-resistance but also
in MTX and E2SO4 transport activity [233] but did not aﬀect
substrate binding. Mutations of R1202 and G1204 (TM16) im-
paired insertion of the protein into the membrane bilayer or
caused aberrant TM helix packing and misfolding, respec-
tively. The E1204 side chain was critical for establishing interh-
elical hydrogen binding or ion pair interactions that are
important for substrate transport as well as stable membrane
expression of the protein and could play a role in the signaling
between the substrate translocation pathway and NBD2.
Mutation of R1249 impaired MRP1-mediated LTC4 transport
and reduced vincristine resistance [219]. This residue was pre-
dicted to be at the membrane–cytosol interface of TM16 and
TM17 and seems to be critical for the architecture of the sub-
strate-binding site(s). Other mutations either aﬀected the trans-
port of LTC4 and/or E217G (Y1243F) or reduced resistance to
drugs (Y1236F, T1241A and Y1243F), suggesting that resi-
dues of the cytoplasmic half of TM17 with side chain hydrogen
bonding potential participate in the formation of a substrate-
binding site [218].
Mutation of W1246 (TM17) eliminated E217G transport
and drug-resistance while LTC4 transport was not aﬀected
[228]. W1246 is also important for binding of LY475776, an
intrinsically photoactivable isoxazole modulator [227]. Alanine
substitution of W445 (TM8), W553 (TM10) and W1198
(TM16) eliminated or substantially reduced transport levels
of organic anion substrates. In contrast, alanine substitutions
of W361 (TM7) and W459 (TM9) caused a more moderate
and substrate-selective reduction in function. More conserva-
tive substitutions (tyrosine and phenylalanine) of W445,
W553 and W1198 resulted in substrate-selective retention of
transport in some cases (W445 and W1198) but not others
(W553) [228]. There is some evidence for a functional interac-
tion between TM17 and TM14. Zhang et al. [235] demon-
strated that E1089 (TM14) was essential for anthracycline
resistance and for transport conjugated organic anions such
as LTC4 and E217G. T1242 (TM17) is important for E217G
and LTC4 transport and a highly speciﬁc functional relation-
ship between TM14 and TM17 for resistance to chemothera-
peutic drugs.
Y1189 and Y1190 (CL7), unlike the corresponding residues
in SUR1, are not involved in its diﬀerential sensitivity to sulfo-
nylureas but nevertheless may be involved in the transport
activity of MRP1 especially with respect to GSH [12]. When
mutated, another residue from CL7, P1150, reduced the trans-
port of LTC4, GSH but enhanced MTX and E217G transport.
These data showed the importance of CL7 amino acids for the
organic anion transport activity by coupling the activity of the
NBDs to the translocation of diﬀerent substrates across the
membranes [229].
Conseil et al. [42] analyzed the natural polymorphisms
occurring in MRP1. One of these polymorphisms, G1299T,
which resulted in the substitution of R433 at the cytosolic
interface of TM8 with a serine residue, signiﬁcantly decreased
the transport of several organic anions but increased doxoru-
bicin resistance [231]. G128C (which results in a conservative
substitution of C43 (TM1) with serine) impaired the plasma
membrane localization [224,236]. Mutagenesis of I1491,
L1488, F1521 and the dileucine motif L1514–L1515 decreased
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lysis at NBD2 [237].3.5. HsMRP2
Replacement of basic residues (K324 (TM6), K483 (TM9),
R1210 (TM16) and R1257 (TM17)) with alanine decreased
the ability to transport an organic anion substrate, glutathi-
one-methlyﬂuorescein and K578A resulted in decreased pro-
tein expression. An inhibitor, cyclosporine A, failed to
inhibit R1230A speciﬁcally, indicating the existence of its bind-
ing site within TM16 [238].
The TMD0 domain is required for correct cellular targeting
to the apical membrane but is not necessary for transport func-
tion [239]. The missense mutation C1302T results in an amino
acid exchange, R768W, which causes a deﬁcient maturation of
the protein leading to a diminished glycosylation, impaired
sorting to the apical membrane and degradation via the pro-
teasome pathway. It is therefore responsible for the defect in
transporting bilirubin conjugates [240]. R1150H and I1173F
mutations eliminated transport activity in vitro. In addition,
the I1173F mutant protein also existed predominantly in an
underglycosylated form that was retained in the ER [241].
Mutation of W1254 (TM17) altered substrate speciﬁcity and
resulted in loss of methotrexate transport activity [220]. Zelcer
et al. [242] also reported that the transport of E217G, which
binds to TM17 [220], was modulated by glibenclamide, proba-
bly via allosteric interaction.3.6. P-glycoprotein
Loo and Clarke have mutated each of the prolines, phenyl-
alanines or glycines. P223 (TM4) and P866 played critical roles
in the transport of colchicine and a mutation at P709 aﬀected
the structural integrity of the protein [243]. Mutating F335
(TM6) and F983 (TM12) drastically altered drug-resistance
proﬁles and F983 has been shown to contribute to distinct
mechanisms of inhibition by stereoisomers of ﬂupentixol
[5,244]. Glycine residues have been shown to play important
roles for structure and function; the naturally occurring
G185V mutation located between the TM2 and TM3 and
other glycines such as G141, G830 resulted in increased resis-
tance to colchicine and decreased resistance to vinblastine
[5,93,245]. Omote et al. [246] explained this result by the fact
that G185 is a pivotal point in transmitting conformational
changes between the catalytic sites and the colchicine drug-
binding domain. Mutations in the CLs have been reported to
alter substrate speciﬁcity of the protein [32,247].
Later structural studies have stressed the importance of both
TM6 and TM12 in forming the binding site for transported
substrates [32,248–250]. Furthermore, chemical cross-linking
experiments have demonstrated a physical proximity of TM6
and TM12 when mutating P350C (TM6) and S993C (TM12)
[248]. One recent model suggests that TMs 1, 4, 5, 6, 8, 10,
11 and 12 but also some amino acids in cytoplasmic regions
of the protein line a central pore and contribute to substrate
binding with a predominance for TMs 5, 6, 11 and 12
[245,247–249,251]. The pattern obtained after cross-linking
studies suggests that TM6 is close to TMs 10, 11 and 12, while
TM12 is close to TMs 4, 5 and 6 [251]. Diﬀerent residues are
important for the substrate binding: S222 (TM4), I306
(TM5), L339 and A342 (TM6), I868 and G872 (TM10),
F942 and T945 (TM11) and L975, V982 and A985 (TM12)[251]. Rothnie et al. [252] demonstrated that the coupling
mechanism involves residue L339 in TM6. Indeed, the covalent
modiﬁcation of this residue prevented conformational changes
that lead to drug stimulation of ATP hydrolysis. TM6 is an
integral part of the protein pore and both sides of the helix,
hydrophobic and hydrophilic, faces mediate the function
[253]. TM9 is cooperating with TM6 to mediate drug resis-
tance [254]. ATP hydrolysis promoted the interaction between
the extracellular ends of TM1 and TM11 as shown by mutat-
ing M68 and M69 (TM1) and Y950C, Y953, A954, F957
(TM11) into cysteines followed by cross-linking experiments
of diﬀerent combinations of these mutants [255]. These studies
suggested that conformational rearrangement of TM11 may
contribute to the release of drug substrate during ATP hydro-
lysis. Models of packing the TMs segments have been pro-
posed by the authors summarizing their results.
Loo et al. [256] demonstrated that mutations aﬀecting the
processing and targeting of Pgp disrupted interactions between
the NBDs such as in DY490, G269V (ICL2), P709G (linker),
G722A (TM7) and A841L (TM9). The activities of such mis-
processed mutants were restored when the mutants were grown
in the presence of drug substrate cyclosporine. The major
cyclosporine binding site seems to be localized between the
end of TM11 and the end of TM12 [257]. Another mutation,
A339P, has been demonstrated to decrease the sensitivity to
cyclosporine [258]. Loo et al. [259] demonstrated, by mutating
L1260, that the COOH-terminal dileucine motif is not a plas-
ma membrane targeting signal as for CFTR and SUR and that
it is required for proper folding of the protein but not for its
activity.4. Conclusions and perspectives
Disease-causing mutations in CFTR, SUR or MRP have
ultimately strongly contributed to our knowledge on ABC
transporter functions since they identify protein changes neces-
sary for proper functioning. Apart from natural variation and
polymorphisms, site-directed mutagenesis has been used as a
tool to (i) identify important Aa’s not hit by natural variation,
(ii) test comparable/homologous mutations in related ABC
transporters (as exempliﬁed by the introduction of deletions
corresponding to DF508 in CFTR) or the eﬀect of the replace-
ment of an individual amino acid with a range of diﬀerent ami-
no acids in order to reﬁne its speciﬁcity. In the last decades,
recombinant techniques, diﬀerent human cell lines or heterolo-
gous system such as baculovirus-infected insect cells reduced
the experimental eﬀort to reliably overexpress these large mem-
brane proteins. Apart from classical cellular and vesicle trans-
port experiments or biophysical analysis with the patch-clamp
technique a large number of biochemical tools such as photo-
aﬃnity labelling, cross-linking studies, vanadate trapping, dif-
ferent immunological or spectroscopic methods as well as cell
biological and microscopic tools have been applied to analyse
the function of wild-type and mutant ABC proteins. In doing
so, the phenotypical investigation of the contribution of single
amino acids and thus the analytical resolution is continuously
as well improving as expanding which is reﬂected by the large
number of publications in this ﬁeld. However, most of the con-
tributions identiﬁed during the preparation of this review focus
on functional details such as the analysis of the hydrolytic cy-
cle of ATP, transport and electrophysiological characteristics,
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seems evident that the integration of available biochemical
data into a good functional model is missing mainly because
two major aspects in ABC transporter function still await elu-
cidation. First, in the classical transporters, especially the
ABCC/MRP-related transporters, the substrate-binding site
is not clearly deﬁned. As can be seen from Fig. 5, almost all
TMD1 and 2 TM spans of HsMRP1 have been identiﬁed to
be important for transport. In many cases individual muta-
tions cause aﬃnity changes and variations in transport activi-
ties towards selected but not all possible substrates. Second, in
many cases it is not evident whether mutations resulting in loss
of activity and which do not aﬀect ATP hydrolysis in the
NBDs are involved in substrate binding, formation of the
translocation pore or whether they couple the ATP-dependent
power stroke to conformational changes resulting in substrate
translocation towards the extracellular face. Thus, the ener-
getic coupling between ATP-hydrolysis and the transport event
needs further experimental elucidation.
Ultimately, available biochemical data needs conﬁrmation
by structural models and vice versa. To this end, only two
high-resolution structures of bacterial ABC transporters con-
sisting of NBDs and TMDs have been resolved of which the
structure of the Escherichia coli vitamin B12 transporter com-
plex BtuCD resembles best the X-ray structure of the NBD di-
mer of isolated NBDs and meets biochemical and
physiological data with respect to ATP binding and the cata-
lytic cycle [260–265]. In contrast, high-resolution structures
for eukaryotic ABC transporters are not available. However,
low-resolution structures for Pgp [266,267], CFTR [268] and
the Kir6.2-SUR1 complex [269] allow an overall survey of
the ABC transporter molecules and demonstrate structural
homology. Furthermore, Pgp undergoes large structural rear-
rangements of the TM helices upon nucleotide binding reﬂect-
ing coupling between ATP hydrolysis and drug binding
[266,267]. The recent reﬁnement of the Pgp structure to 8 A˚ ap-
pears to conﬁrm the importance of TM6 and 12 in drug bind-
ing as demonstrated before by cross-linking and extensive
mutagenesis studies [270]. The power of the integration of bio-
chemical and structural data was recently exempliﬁed by Hig-
gins and Linton [271] who suggested the novel catalytic ‘ATP
switch’ model presenting a framework to study the coupling
between ATP binding and hydrolysis to substrate binding,
transport and release. According to this model, the velocity
to switch between two major conformations of the NBDs
(closed NBD dimer conformation with two bound ATPs at
the dimer interface and dissociation to an open dimer facili-
tated by ATP hydrolysis) requires signals coming from the
TMDs.
Since the catalytic cycle of an ABC transporter is rather
complex and structural analysis at high resolution is hampered
by technical diﬃculties it is a great challenge to identify the
conformational changes associated with individual catalytic
steps. In this respect, the analysis of mutants will help to iden-
tify catalytic states where the molecule has been trapped in a
certain step of the reaction cycle. Thereby mutants may reduce
the number of conformational intermediates that need to be
processed for structure elucidation. On the other hand, the
large amount of biochemical mutant data will allow the veriﬁ-
cation of the plausibility of structural models in the future or
reinduce further mutagenesis studies to test the signiﬁcance
of three-dimensional structures.Acknowledgements: Work in our laboratory is supported by the Na-
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